Goldman Sachs analysts note that the garadacimab (CSL312) product has the potential to be a "pipeline in a product" thanks to multiple end use possibilities.
CSL312 is a humanised anti-factor XIIa monoclonal antibody in development for multiple indications including as a subcutaneous therapy for HAE, with the potential for administration every 4 weeks (vs. every 2-3 days for Haegarda). Given its early position in the coagulation cascade, there is also potential application in various other disorders (including fibrosis, cardiovascular and inflammatory indications).
News: CSL CSL Ltd Says Garadacimab Received FDA And EMA Filing Acceptance, page-4
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$306.60 |
Change
4.560(1.51%) |
Mkt cap ! $148.1B | |||
| Open | High | Low | Value | Volume |
| $303.41 | $306.68 | $303.01 | $215.1M | 707.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3499 | $306.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $306.68 | 284 | 2 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |